Praxis Precision Medicines

Edit info

Founded: 2015

Location: Boston, MA

Employee range: 50 - 200

Clinical stage: Clin2

Therapy area: Parkinson's

Drug types: NEU, PED

Lead product: Ulixacaltamide

Funding: $59M stock Jun 2023; $219M IPO Oct 2020; $110M C1 Jul 2020; $100M total May 2020

Investors: Blackstone Life Sciences, Novo Holdings, Vida Ventures, Eventide

praxismedicines.com

linkedin.com

job board

Business:

Genetic Neuroscience Treatments

Drug notes:

Also Clin2 essential tremor; PRAX-562 Clin2 epilepsy; PRAX-628 Clin1 focal epilepsy; PRAX-222 Clin1 epilepsy; 6 programs Clin0 CNS disorders

About:

Praxis Precision Medicines is developing therapies for central nervous system (CNS) disorders by using insights from genetics. CNS disorders are characterized by neuronal excitation-inhibition imbalance. Praxis is using four key principles to increase the probability of success of finding therapies: [1] genetics to focus on targets identified through human genetics, [2] translational tools, to validate targets, [3] patient-guided development strategies and [4] efficient and rigorous clinical development paths. Praxis currently has two lead clinical programs for Epilepsy - CerebrumTM, a small molecule platform and SolidusTM, an antisense oligonucleotide platform.